ACRX - AcelRx Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

AcelRx Pharmaceuticals, Inc.

351 Galveston Drive
Redwood City, CA 94063
United States
650-216-3500
http://www.acelrx.com

SectorHealthcare
IndustryMedical Devices
Full Time Employees57

Key Executives

NameTitlePayExercisedYear Born
Mr. Vincent J. AngottiCEO & Director765.49kN/A1968
Dr. Pamela Pierce PalmerCo-Founder, Chief Medical Officer & DirectorN/AN/A1963
Mr. Raffi Mark AsadorianChief Financial Officer396.2kN/A1969
Mr. Lawrence G. HamelChief Devel. OfficerN/AN/A1952
Mr. Anil N. DasuChief Engineering OfficerN/AN/A1963
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Corporate Governance

AcelRx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.